Insmed has closed a public offering of common stock that generated net proceeds of ~$377.7 million, the company said. The proceeds will be used in large part for continued development, regulatory submissions, and potential commercialization of ALIS amicakin liposome inhalation suspension.
According to the announcement, planned uses for the proceeds include “invest in increased third-party manufacturing capacity for and commercial inventory production of ALIS in anticipation of possible commercial launch, initially in the United States and subsequently in Japan and other countries,” “clinical development of INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1,” and “other general corporate purposes, which may include the acquisition or in-license of additional compounds, product candidates, technology or businesses.”
Read the Insmed press release.
